Selective protein kinase inhibitors

A compound of formula (I):

• or a pharmaceutically acceptable salt thereof, wherein:
• A is five or six member heterocycle ring;
• R1 is
• hydrogen;
• halogen;
• a (C1-C10)alkyl group;
• a thio(C1-C10)alkyl group;
• or
• a (C1-C10)alkoxy group;
• R2 is
• halogen;
• an aryl group;
• a halo(C1-C10)alkyl group;
• a (C1-C10)alkyl group,
• wherein the C1-C10 carbons are optionally substituted with at least one heteroatom optionally substituted with a halo(C1-C10)alkyl or a (C1-C10)alkyl,
• wherein the C1-C10 carbons are optionally substituted with a solubilising group;
• a (C1-C10) alkoxy group;
• a thio(C1-C10) alkyl group;
• an halo(C1-C10)alkoxy group;
• —COOR;
• —NRR′;
• —NR—CO—R′;
• —CONRR′;
• —SO2NRR′;
• —NR—SO2—R′
• wherein R and R′ are each independently selected from the group consisting of
• hydrogen,
• aryl group,
• heteroaryl group, and
• a (C1-C10)alkyl group optionally substituted with at least one heteroatom optionally substituted with a (C1-C10)alkyl group optionally substituted with a solubilising group;
• a heterocycle group;
• or
• a solubilising group;
• R3 is
• hydrogen;
• halogen;
• cyano;
• a (C1-C10)alkyl group;
• a (C1-C10)alkoxy group;
• —CF3;
• —NRR′;
• —NR—CO—R′;
• —CONRR′;
• —SO2NRR′;
• a heterocycle group;
• or
• a solubilising group;
• wherein R and R′ are each independently hydrogen or a (C1-C10)alkyl group optionally substituted with at least one heteroatom optionally substituted with a (C1-C10)alkyl group optionally substituted with a solubilising group;
• Q is O or S;
• W is N or CR4;
• wherein R4 is
• hydrogen;
• cyano;
• —CF3;
• halogen;
• a thio(C1-C10)alkyl group;
• a (C1-C10)alkyl group that is optionally substituted with at least one heteroatom optionally substituted with a (C1-C10)alkyl group that is optionally substituted with a solubilising group;
• a (C1-C10)alkoxy group;
• a halo(C1-C10)alkoxy group;
• a solubilising group;
• an heterocycle;
• —CO—NRR′;
• —SO2—NRR′;
• —NRR′;
• —NR—CO—R′;
• or
• —NR—SO2R′,
• wherein R and R′ are each independently
• hydrogen,
• a (C1-C10)alkyl group optionally substituted with at least one heteroatom optionally substituted with a (C1-C10)alkyl group that is optionally substituted with a solubilising group, or
• a heterocycle group;
• X is N or CR5;
• and
• wherein R5 is
• hydrogen;
• cyano;
• halogen;
• a (C1-C10)alkyl group;
• a (C1-C10)alkoxy group;
• —CO—OR;
• or
• —CO—NRR′,
• wherein R and R′ are each independently selected from
• hydrogen,
• (C1-C10)alkyl group optionally substituted with at least one heteroatom optionally substituted with a (C1-C10)alkyl group optionally substituted with a solubilising group or
• a heterocycle group.